Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 7:54 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 500 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Type 2
Interventions
Technosphere Insulin Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Type 1 Diabetes Mellitus
Interventions
Sham Injection, Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
No treatment
Device
Lead sponsor
Abbott Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Escondido, California • Walnut Creek, California • Atlanta, Georgia + 1 more
Conditions
Type 1 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions
GlucoSTAT
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
Interventions
NovoFine® needle 6 mm, Ultra-Fine needle 12.7 mm
Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Walnut Creek, California • Berlin, New Jersey • Lawrenceville, New Jersey + 2 more
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
107
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 104 more
Conditions
Gastroparesis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Placebo, 10mg TZP-102, 20mg TZP-102
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 27 more
Conditions
Diabetes Mellitus, Type 2
Interventions
placebo, BI1356 low dose, BI1356 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
10 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
San Antonio, Texas • Norfolk, Virginia
Completed Phase 3 Interventional Results available

Adjunctive Metformin Therapy in Double Diabetes

NCT01334125
Conditions
Diabetes Mellitus
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
10 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Obesity, Type 2 Diabetes
Interventions
Cagrisema, Semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
99
States / cities
Birmingham, Alabama • Pelham, Alabama • Gilbert, Arizona + 81 more
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro Protamine Suspension, Insulin Levemir
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Idaho Falls, Idaho • Springfield, Illinois • Topeka, Kansas + 1 more
Completed No phase listed Observational Accepts healthy volunteers

Noninvasive Transcutaneous Glucometer Development

NCT01168076
Conditions
Healthy, Prediabetic State (IGT), Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
Not listed
Lead sponsor
InLight Solutions
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Obesity or Overweight
Interventions
Lenbelintide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
41
States / cities
Dothan, Alabama • Huntsville, Alabama • Mesa, Arizona + 38 more
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo matching Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
12
States / cities
Chula Vista, California • San Diego, California • Torrance, California + 9 more
Conditions
Type 2 Diabetes Mellitus, Renal Impairment
Interventions
LX4211, LX4211 Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
6
States / cities
Anniston, Alabama • Chula Vista, California • Edgewater, Florida + 3 more
Conditions
Diabetic Macular Edema
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
NNC 90-1170
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
30 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Type 1 Diabetes
Interventions
Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks, Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks, No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks, No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks
Combination Product · Device
Lead sponsor
Ananda Basu, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Interventions
Omnipod 5 System, Omnipod 6 System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
14 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Santa Barbara, California • Aurora, Colorado + 8 more
Conditions
Diabetic Gastroparesis
Interventions
10 mg TZP-102, Placebo
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Huntsville, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 19 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects

NCT02820298
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lakewood, Colorado
Conditions
Diabetes Mellitus, Type 2
Interventions
AMG 127, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Lake Forest, California • Aventura, Florida
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
14 Years to 40 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
I-PORT, standard injections
Device · Other
Lead sponsor
Texas Diabetes & Endocrinology, P.A.
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Austin, Texas